Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune Microenvironment in Gallbladder Adenocarcinomas

Immune Microenvironment in Gallbladder Adenocarcinomas Programmed death-1 (PD1) expression has not been reported in gallbladder adenocarcinoma. In this study we examined PD1 expression in gallbladder cancer to explore the correlation between PD1 expression and the clinicopathologic parameters. We found that 98% (46/47) cases expressed programmed death-ligand 1 (PD-L1) with 85% cases being PD-L1 3+. PD1+ tumor-infiltrating lymphocytes (TILs) were present in 78.7% cases (37/47). The tumor size was significantly smaller and the stromal CD3+ TILs were significantly higher in tumors with PD1+ TILs than those with PD1− TILs. In the tumors with size of <3 cm, stromal CD3+ TILs >115/HPF or stromal CD8+ TILs >45/HPF were associated with much better survival than those with stromal CD3+ TILs ≤115/HPF or stromal CD8+ TILs ≤45/HPF. In tumors with the size of 3 cm or larger, PD1+ TILs or stromal CD8+ TILs >45/HPF carried a significantly poorer survival than PD1− tumors or stromal CD8+ TILs <=45/HPF. No correlation was identified between PD1 expression and lymphovascular invasion, distant metastasis, pathologic tumor stage or prognostic stage. Multivariate survival analysis showed that tumor TNM stage and age were independent prognostic factors in gallbladder adenocarcinomas. We conclude that gallbladder adenocarcinomas may have high PD-L1 expression and PD1+ TILs. Smaller tumor size and greater amount of stromal CD3+ T cells were found in tumors with PD1+ TILs. In small tumors (<3 cm), high stromal CD3+ TILs or high stromal CD8+ TILs were associated with better survival. However, in large tumors (≥3 cm), PD1+ TILs or high stromal CD8+ TILs carried a poorer survival. Our study implied that immune-based therapy including PD1/PD-L1 checkpoint blockade might be useful in gallbladder adenocarcinomas. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry Wolters Kluwer Health

Immune Microenvironment in Gallbladder Adenocarcinomas

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/immune-microenvironment-in-gallbladder-adenocarcinomas-3GECKp0uOk

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1062-3345
eISSN
1533-4058
DOI
10.1097/pai.0000000000000922
Publisher site
See Article on Publisher Site

Abstract

Programmed death-1 (PD1) expression has not been reported in gallbladder adenocarcinoma. In this study we examined PD1 expression in gallbladder cancer to explore the correlation between PD1 expression and the clinicopathologic parameters. We found that 98% (46/47) cases expressed programmed death-ligand 1 (PD-L1) with 85% cases being PD-L1 3+. PD1+ tumor-infiltrating lymphocytes (TILs) were present in 78.7% cases (37/47). The tumor size was significantly smaller and the stromal CD3+ TILs were significantly higher in tumors with PD1+ TILs than those with PD1− TILs. In the tumors with size of <3 cm, stromal CD3+ TILs >115/HPF or stromal CD8+ TILs >45/HPF were associated with much better survival than those with stromal CD3+ TILs ≤115/HPF or stromal CD8+ TILs ≤45/HPF. In tumors with the size of 3 cm or larger, PD1+ TILs or stromal CD8+ TILs >45/HPF carried a significantly poorer survival than PD1− tumors or stromal CD8+ TILs <=45/HPF. No correlation was identified between PD1 expression and lymphovascular invasion, distant metastasis, pathologic tumor stage or prognostic stage. Multivariate survival analysis showed that tumor TNM stage and age were independent prognostic factors in gallbladder adenocarcinomas. We conclude that gallbladder adenocarcinomas may have high PD-L1 expression and PD1+ TILs. Smaller tumor size and greater amount of stromal CD3+ T cells were found in tumors with PD1+ TILs. In small tumors (<3 cm), high stromal CD3+ TILs or high stromal CD8+ TILs were associated with better survival. However, in large tumors (≥3 cm), PD1+ TILs or high stromal CD8+ TILs carried a poorer survival. Our study implied that immune-based therapy including PD1/PD-L1 checkpoint blockade might be useful in gallbladder adenocarcinomas.

Journal

Applied Immunohistochemistry – Wolters Kluwer Health

Published: Sep 12, 2021

References

  • Gallbladder carcinoma: Prognostic factors and therapeutic options
  • Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes
  • Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
  • Molecular and biochemical aspects of the PD-1 checkpoint pathway
  • The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
  • Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors
  • Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports
  • Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers
  • Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy
  • Carcinoma of the gallbladder
  • New molecular and immunotherapeutic approaches in biliary cancer
  • Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part II: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, Genitourinary carcinomas, and primary brain tumors
  • Cancer classification using the immunoscore: a worldwide task force
  • The immune contexture in human tumours: impact on clinical outcome
  • Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
  • Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
  • Ramucirumab Plus Pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)
  • Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
  • Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer
  • Early detection of metachronous bile duct cancer in Lynch syndrome: report of a case
  • Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  • PD-1 Blockade in tumors with mismatch-repair deficiency
  • Low frequency of mismatch repair deficiency in gallbladder cancer
  • Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies